-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, N2+ug+WsScJ+KphofZrNVfN0Ms8GsVALXKiK0faVSdDac1kE9DCtOWVAQE47rBDZ MGfvvqcRy0pdhaukBJ5utw== 0000000000-07-037166.txt : 20070907 0000000000-07-037166.hdr.sgml : 20070907 20070731120214 ACCESSION NUMBER: 0000000000-07-037166 CONFORMED SUBMISSION TYPE: UPLOAD PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070731 FILED FOR: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: UPLOAD BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 PUBLIC REFERENCE ACCESSION NUMBER: 0001104659-07-013940 LETTER 1 amylinnfcletter.pdf NO FURTHER COMMENT LETTER DATED 7/31/2007 begin 644 amylinnfcletter.pdf M)5!$1BTQ+C0-)>+CS],-"C8@,"!O8FH@/#PO3&EN96%R:7IE9"`Q+TP@,3`V M,3-IB8&#@86!@6L``!*+_ M&5`!,Q"S,'`T,#`A"?)`,0.#$@,/ZX%$CL+)#,S"$ES>?`H7>!.TP#*,#`P2 M\X$T2)\%$+,R,*B;0<09W@`$&`#+QPDE#0IE;F1S=')E86T-96YD;V)J#3<@ M,"!O8FH\/"]-971A9&%T82`T(#`@4B]086=E7!E+T-A=&%L M;V%LP(#`@-C$R(#%LP(#`@-C$R(#$7AX1!/!S2T1"RC7,QKB/(:V`T9#R)])K6 MJO/289#E^K%S"+C9;QUN:,,Q6.+/\VF20#9II_$%ISSL7V2?/C(898S%.H77 MF3MG1IX*`:G(ZV+CCFA(BK4$4<[A.YU2N!?%&MQ?V:W9WZ,S[Z=-]0(1XPS. MY/S/G]OM>@\!'X"O>7Q,.>@I!Y;RO=+4U!^XH6Y(`P)IM99-(PY4[6K?$&XM M9#U]>AA`6I2BS&V-QNFWXTR<'S)I4V>ZTD5-R'Y=E/"P$LJZ(I?;ILC%NC;I M!RZVD<"7,J=]L77:/AXS\4@21-B`:E=*&,NR41(FJGB5'8A_P!8E3`JYK`8P MOH+$YSX_H#X57-0)3FLKTMKJ@WI]U!EYE)?@>MP/&;+L"?;,@EZJ1^(C M::4VP)EW!XM*0;.26-X:]\)/*1199JJ[=T0E;C29%W&X!=IJ7CV?G3 M@_^^2XG-_4/"2J!"\FKS@GFQ1M56@9*OA=Q!M8"]=G4;W!&Q5/F(!GZ'X/SY MP8ZY""0F=^88F`1E!8NMPA8JG4OKG!.4:`VBP<86=5O_-OJ;DFF9'3K1X#V4 M8`-EJYRVWGW'3JKNT]C4?-;=.E,7>\FQ_04:PYB.2.F:[N;:'Z$O.T,9P_AA M@/ZZV[&W.P9V>'L'GMXS)Q!N=9P$(8@NTT9'BH]SU]T:L$D>]>"3RGJ'6;,^ MZ$D\V^$]A>5[I`<](+AA,FIUWE9(E@4>.+OEJJZ+NA%ET_KC52$7W5R>5]OR M:/+513=Q;' M?V_)GI"5L,-C#5N`L`:0-6QAD1T$40A)"`$20DC8!4%$!11%1(2JE3+6;71& M3T6=+JYCK0[6?>K2`_4PZN@XM!;7CIT7.$>=3F>FT^\?[_= M\P"@)Z6JM=4P"P"-UJ#/2HS%%A448J0)``,*(`(1`#)YK2XM.R$'X)+&2[!: MW`G\BYY>!Y!IO2),RL`P\/^)+=?I#0!`&3@'*)2U:65 M)H91$^OQ!'&V-+%JGKWG?.8YVL0*C5:!LREGG4*C,/%IG%?7&94X(ZDX=]6I ME?4X7\79I/\W!2K4F"@T5(PE*>NKE`:#,$,FKY3I%9BD6J.3:1L! MF+_SG#BFVF)XD8-%H<'!0G\?T3N%^J^;OU"FWL[3D\RYGD'\"V]M/^=7/0J` M>!:OS?JWMM(M`(RO!,#RYEN;R_L`,/&^';[XSGWXIGDI-QAT8;Z^]?7U/FJE MW,=4T#?ZGPZ_0.^\S\=TW)OR8''*,IFQRH"9ZB:OKJHVZK%:G4RNQ(0_'>)? M'?CS>7AG*J46C\C#ITRM5>'MUBK4!G6U%E-K_U,3?V783S0_U[BX8Z\! MK]@'L"[R`/*W"P#ET@!2M`W?@=[T+962!S+P-=_AWOS;`+#8#L8`[O!?G`0C(./P0GP1W`>?`FN@5M@$DR# MAV`&/`6O(`@B00R("UE!#I`KY`7Y0V(H$HJ'4J$LJ``J@520%C)"+=`*J`?J MAX:A'=!NZ/?04>@$=`ZZ!'T%34$/H.^@ES`"TV$>;`>[P;ZP&(Z!4^`<>`FL M@FO@)K@37@E&!I%19#]R##F+7$$FD4?("Y2(@6=0F?0UP0&P9;@10@C2`F+""I"/:&+,$C82?B(<(9PC3!->$HD$OE$`3&$ MF$0L(%80FXF]Q*W$`\3CQ$O$N\19$HED1?(B19#223*2@=1%VD+:1_J,=)DT M37I.II$=R/[D!'(A64ON(`^2]Y`_)5\FWR._HK`HKI0P2CI%06FD]%'&*,IMZA,:C>9$"Z5ETM2TY;0AVN]HG].F M:"_H'+HG74(OHAOIZ^@?TH_3OZ(_83`8;HQH1B'#P%C'V,TXQ?B:\=R,:^9C M)C53F+69C9@=-KML]IA)8;HR8YA+F4W,0>8AYD7F(Q:%Y<:2L&2L5M8(ZRCK M!FN6S66+V.EL#;N7O8=]CGV?0^*X<>(Y"DXGYP/.*:1^0)>%)>!:^']UO>!&_&G&,>:)YGWF`^8OZ)^20?X;OQI?PJ?A__(/\Z M_Z6%G46,A=)BC<5^B\L6SRQM+*,ME9;=E@NMMUF?L7YDP[,)MY';=-LW MQ>Z4W2-[OGVT?87]@/VG]@\OZS$W@EN^VRFW<[;[`4B`5-`GV"FZ[,]RCW&O<1]VO>A`]Q!Z5'EL] MOO2$/8,\RSU'/"]ZP5[!7FJOK5Z7O`G>H=Y:[U'O&T*Z,$98)]PKG/+A^Z3Z M=/B,^SSV=?$M]-W@>];WM5^07Y7?F-\M$4>4+.H0'1-]Y^_I+_R$WQ#QQ MAKA7_'DH(30VM"WTX]`78<%AAK"#87\/%X97AN\)O[]`L$"Y8&S!W0BG"%G$ MCHC)2"RR)/+]R,DHQRA9U&C4-]'.T8KHG='W8CQB*F+VQ3R.]8O5QWX4^TP2 M)EDF.1Z'Q"7&=<=-Q'/B<^.'X[].<$I0)>Q-F$D,2FQ./)Y$2$I)VI!T0VHG ME4MW2V>20Y*7)9].H:=DIPRG?)/JF:I//98&IR6G;4R[O=!UH7;A>#I(EZ9O M3+^3(J"(X6DPKS"G86SB^,7;UH\7114U%5T M?8E@2<.26419?]E]581JH^I!>53Y8/DCM40]K/ZV(JEB>\6SRO3* M#RM_K,JO.J`A:THT1[4<;:7V=+5]=4/U)9V7KDLW61-6LZEF1I^BWUD+U2ZI M/6+@X3]3%XSNQI7&J;K(NI&ZY_5Y]8<:V`W:A@N-GHUK&N\U)33]IAEMEC>? M;'%L:6^96A:S;$K+-N:VS;7IYXO)=[=3VRO8_=?AU]'=\OR)_Q;%. MN\[EG7=7)J[^ZL2I\U?;5Z&KUZHDU`6NVK'G=K>C^HL>O9[#GAUYY M[Q=K16N'UOZXKFS=1%]PW[;UQ/7:]== M9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;] MIVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;& MP\=!Q[_(/%$XIZ#+HO.E& MZ=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#U MWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW__P(,`/>$\_L* M#0IE;F1S=')E86T-96YD;V)J#3$V(#`@;V)J/#PO4W1E;58@,3$V+C@V-R]& M;VYT3F%M92]4:6UE2A4:6UE'1'4W1A=&4O4T$@9F%LFMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB,RXQ+3&UL;G,Z>&%P/2)H='1P.B\O;G,N M861O8F4N8V]M+WAA<"\Q+C`O(CX*("`@("`@("`@/'AA<#I#&%P.D-R96%T;W)4;V]L M/@H@("`@("`@("`\>&%P.DUO9&EF>41A=&4^,C`P-RTP-RTS,50Q,CHP,3HT M-BTP-#HP,#PO>&%P.DUO9&EF>41A=&4^"B`@("`@("`@(#QX87`Z0W)E871E M1&%T93XR,#`W+3`W+3,Q5#$R.C`Q.C0V+3`T.C`P/"]X87`Z0W)E871E1&%T M93X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@("`@(#QR9&8Z1&5S8W)I M<'1I;VX@&UL.FQA;F<](G@M9&5F875L="(^36EC&%P34TZ26YS=&%N8V5)1#YU=6ED M.CDX9#EE,65D+3(Q8V0M-#&%P34TZ M26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#PO6QI;B!.1D,@;&5T=&5R(%\R7RYD;V,I/CX-96YD;V)J M#7AR968-"C`@-@T*,#`P,#`P,#`P,"`V-34S-2!F#0HP,#`P,#`V-# -----END PRIVACY-ENHANCED MESSAGE-----